A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Clinical trial NCT07015242 · RECRUITING
Trial details
- NCT number
- NCT07015242
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-06
- Primary completion
- 2028-01-09
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.